|
1
|
Pollak M: The insulin and insulin-like
growth factor receptor family in neoplasia: An update. Nat Rev
Cancer. 12:159–169. 2012.PubMed/NCBI
|
|
2
|
Cornellà H, Alsinet C and Villanueva A:
Molecular pathogenesis of hepatocellular carcinoma. Alcohol Clin
Exp Res. 35:821–825. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cervello M, McCubrey JA, Cusimano A,
Lampiasi N, Azzolina A and Montalto G: Targeted therapy for
hepatocellular carcinoma: Novel agents on the horizon. Oncotarget.
3:236–260. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chang AY and Wang M: In-vitro growth
inhibition of chemotherapy and molecular targeted agents in
hepatocellular carcinoma. Anticancer Drugs. 24:251–259. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cohen BD, Baker DA, Soderstrom C,
Tkalcevic G, Rossi AM, Miller PE, Tengowski MW, Wang F, Gualberto
A, Beebe JS and Moyer JD: Combination therapy enhances the
inhibition of tumor growth with the fully human anti-type 1
insulin-like growth factor receptor monoclonal antibody CP-751,871.
Clin Cancer Res. 11:2063–2073. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lin RX, Wang ZY, Zhang N, Tuo CW, Liang
QD, Sun YN and Wang SQ: Inhibition of hepatocellular carcinoma
growth by antisense oligonucleotides to type I insulin-like growth
factor receptor in vitro and in an orthotopic model. Hepatol Res.
37:366–375. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rodon J, DeSantos V, Ferry RJ Jr and
Kurzrock R: Early drug development of inhibitors of the
insulin-like growth factor-I receptor pathway: Lessons from the
first clinical trials. Mol Cancer Ther. 7:2575–2588. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen KF, Yeh PY, Yeh KH, Lu YS, Huang SY
and Cheng AL: Down-regulation of phospho-Akt is a major molecular
determinant of bortezomib-induced apoptosis in hepatocellular
carcinoma cells. Cancer Res. 68:6698–6707. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
van Malenstein H, Dekervel J, Verslype C,
Van Cutsem E, Windmolders P, Nevens F and van Pelt J: Long-term
exposure to sorafenib of liver cancer cells induces resistance with
epithelial-to-mesenchymal transition, increased invasion and risk
of rebound growth. Cancer Lett. 329:74–83. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tai WT, Cheng AL, Shiau CW, Liu CY, Ko CH,
Lin MW, Chen PJ and Chen KF: Dovitinib induces apoptosis and
overcomes sorafenib resistance in hepatocellular carcinoma through
SHP-1-mediated inhibition of STAT3. Mol Cancer Ther. 11:452–463.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gedaly R, Angulo P, Hundley J, Daily MF,
Chen C, Koch A and Evers BM: PI-103 and sorafenib inhibit
hepatocellular carcinoma cell proliferation by blocking
Ras/Raf/MAPK and PI3K/AKT/mTOR pathways. Anticancer Res.
30:4951–4958. 2010.PubMed/NCBI
|
|
12
|
O'Reilly KE, Rojo F, She QB, Solit D,
Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, et al:
mTOR inhibition induces upstream receptor tyrosine kinase signaling
and activates Akt. Cancer Res. 66:1500–1548. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zitzmann K, Rüden Jv, Brand S, Göke B,
Lichtl J, Spöttl G and Auernhammer CJ: Compensatory activation of
Akt in response to mTOR and Raf inhibitors-a rationale for
dual-targeted therapy approaches in neuroendocrine tumor disease.
Cancer Lett. 295:100–109. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Friedman RC, Farh KK, Burge CB and Bartel
DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome
Res. 19:92–105. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lewis BP, Burge CB and Bartel DP:
Conserved seed pairing, often flanked by adenosines, indicates that
thousands of human genes are microRNA targets. Cell. 120:15–20.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pillai RS, Bhattacharyya SN and Filipowicz
W: Repression of protein synthesis by miRNAs: How many mechanisms?
Trends Cell Biol. 17:118–126. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lan FF, Wang H, Chen YC, Chan CY, Ng SS,
Li K, Xie D, He ML, Lin MC and Kung HF: Hsa-let-7g inhibits
proliferation of hepatocellular carcinoma cells by downregulation
of c-Myc and upregulation of p16(INK4A). Int J Cancer. 128:319–331.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Croce CM: Causes and consequences of
microRNA dysregulation in cancer. Nat Rev Genet. 10:704–714. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
He L, He X, Lim LP, de Stanchina E, Xuan
Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D, et al: A microRNA
component of the p53 tumour suppressor network. Nature.
447:1130–1134. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
El Tayebi HM, Hosny KA, Esmat G, Breuhahn
K and Abdelaziz AI: miR-615-5p is restrictedly expressed in
cirrhotic and cancerous liver tissues and its overexpression
alleviates the tumorigenic effects in hepatocellular carcinoma.
FEBS Lett. 586:3309–3316. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Law PT, Ching AK, Chan AW, Wong QW, Wong
CK, To KF and Wong N: MiR-145 modulates multiple components of the
insulin-like growth factor pathway in hepatocellular carcinoma.
Carcinogenesis. 33:1134–1341. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li D, Liu X, Lin L, Hou J, Li N, Wang C,
Wang P, Zhang Q, Zhang P, Zhou W, et al: MicroRNA-99a inhibits
hepatocellular carcinoma growth and correlates with prognosis of
patients with hepatocellular carcinoma. J Biol Chem.
286:36677–36685. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Peng Y, Dai Y, Hitchcock C, Yang X, Kassis
ES, Liu L, Luo Z, Sun HL, Cui R, Wei H, et al: Insulin growth
factor signaling is regulated by microRNA-486, an underexpressed
microRNA in lung cancer. Proc Natl Acad Sci USA. 110:15043–15048.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mazzaferro V, Regalia E, Doci R, Andreola
S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A and
Gennari L: Liver transplantation for the treatment of small
hepatocellular carcinomas in patients with cirrhosis. N Engl J Med.
334:693–699. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
El Tayebi HM, Omar K, Hegy S, El Maghrabi
M, El Brolosy M, Hosny KA, Esmat G and Abdelaziz AI: Repression of
miR-17-5p with elevated expression of E2F-1 and c-MYC in
non-metastatic hepatocellular carcinoma and enhancement of cell
growth upon reversing this expression pattern. Biochem Biophys Res
Commun. 434:421–427. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
De Meyts P: Insulin and its receptor:
Structure, function and evolution. Bioessays. 26:1351–1362. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Durzyńska J: IGF axis and other factors in
HPV-related and HPV-unrelated carcinogenesis (review). Oncol Rep.
32:2295–2306. 2014.PubMed/NCBI
|
|
28
|
Shaw RJ, Lamia KA, Vasquez D, Koo SH,
Bardeesy N, Depinho RA, Montminy M and Cantley LC: The kinase LKB1
mediates glucose homeostasis in liver and therapeutic effects of
metformin. Science. 310:1642–1646. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Oh HK, Tan AL, Das K, Ooi CH, Deng NT, Tan
IB, Beillard E, Lee J, Ramnarayanan K, Rha SY, et al: Genomic loss
of miR-486 regulates tumor progression and the OLFM4 antiapoptotic
factor in gastric cancer. Clin Cancer Res. 17:2657–2667. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang J, Tian X, Han R, Zhang X, Wang X,
Shen H, Xue L, Liu Y, Yan X, Shen J, et al: Downregulation of
miR-486-5p contributes to tumor progression and metastasis by
targeting protumorigenic ARHGAP5 in lung cancer. Oncogene.
33:1181–1189. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Small EM, O'Rourke JR, Moresi V,
Sutherland LB, McAnally J, Gerard RD, Richardson JA and Olson EN:
Regulation of PI3-kinase/Akt signaling by muscle-enriched
microRNA-486. Proc Natl Acad Sci USA. 107:4218–4223. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pang W, Tian X, Bai F, Han R, Wang J, Shen
H, Zhang X, Liu Y, Yan X, Jiang F and Xing L: Pim-1 kinase is a
target of miR-486-5p and eukaryotic translation initiation factor
4E, and plays a critical role in lung cancer. Mol Cancer.
13:2402014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Huang XP, Hou J, Shen XY, Huang CY, Zhang
XH, Xie YA and Luo XL: MicroRNA-486-5p, which is downregulated in
hepatocellular carcinoma, suppresses tumor growth by targeting
PIK3R1. FEBS J. 282:579–594. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ali S, Saleh H, Sethi S, Sarkar FH and
Philip PA: MicroRNA profiling of diagnostic needle aspirates from
patients with pancreatic cancer. Br J Cancer. 107:1354–1360. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Namløs HM, Meza-Zepeda LA, Barøy T,
Østensen IH, Kresse SH, Kuijjer ML, Serra M, Bürger H,
Cleton-Jansen AM and Myklebost O: Modulation of the osteosarcoma
expression phenotype by microRNAs. PLoS One. 7:e480862012.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lim JS, Park SH and Jang KL: Hepatitis C
virus Core protein overcomes stress-induced premature senescence by
down-regulating p16 expression via DNA methylation. Cancer Lett.
321:154–161. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Dong Y and Wang A: Aberrant DNA
methylation in hepatocellular carcinoma tumor suppression (Review).
Oncol Lett. 8:963–968. 2014.PubMed/NCBI
|
|
38
|
Pourdehnad M, Truitt ML, Siddiqi IN,
Ducker GS, Shokat KM and Ruggero D: Myc and mTOR converge on a
common node in protein synthesis control that confers synthetic
lethality in Myc-driven cancers. Proc Natl Acad Sci USA.
110:11988–11993. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Mazzoletti M, Bortolin F, Brunelli L,
Pastorelli R, Di Giandomenico S, Erba E, Ubezio P and Broggini M:
Combination of PI3K/mTOR inhibitors: Antitumor activity and
molecular correlates. Cancer Res. 71:4573–4584. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Floc'h N, Kinkade CW, Kobayashi T, Aytes
A, Lefebvre C, Mitrofanova A, Cardiff RD, Califano A, Shen MM and
Abate-Shen C: Dual targeting of the Akt/mTOR signaling pathway
inhibits castration-resistant prostate cancer in a genetically
engineered mouse model. Cancer Res. 72:4483–4493. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ragusa M, Majorana A, Statello L, Maugeri
M, Salito L, Barbagallo D, Guglielmino MR, Duro LR, Angelica R,
Caltabiano R, et al: Specific alterations of microRNA transcriptome
and global network structure in colorectal carcinoma after
cetuximab treatment. Mol Cancer Ther. 9:3396–3409. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Song L, Lin C, Gong H, Wang C, Liu L, Wu
J, Tao S, Hu B, Cheng SY, Li M and Li J: miR-486 sustains NF-kB
activity by disrupting multiple NF-kB-negative feedback loops. Cell
Res. 23:274–289. 2013. View Article : Google Scholar : PubMed/NCBI
|
